HKPMDC
 All     Test   
 
香港分子病理检验中心
严正声明
香港分子病理检验中心(「本中心」)最近注意到,一间公司(「所述公司」)正通过多个网上商店和平台销售其 RT-PCR(逆转录聚合酶链反应)测试套件(「所述产品」),而在其中一些平台上,所述产品销售的描述提及,检测服务和报告将由HKMPDC等方提供。

本中心特此声明,我们既非所述产品的测试服务或报告提供者,亦与所述公司概无存在任何持续业务关系。对于所述产品的宣传数据(「虚假及误导性信息」)中提及HKMPDC名称,本中心感到诧异,而此属于虚假陈述。

为避免令公众产生任何混淆,本中心已采取行动,要求删除所有在虚假和误导性信息中提及HKMPDC名称的内容,并正寻求对此事进行全面调查。

HKMPDC特此明确保留一切追究权利和补救措施。

香港分子病理檢驗中心
嚴正聲明

香港分子病理檢驗中心(「本中心」)最近注意到,一間公司(「所述公司」)正通過多個網上商店和平台銷售其 RT-PCR(逆轉錄聚合酶鏈反應)測試套件(「所述產品」),而在其中一些平台上,所述產品銷售的描述提及,檢測服務和報告將由HKMPDC等方提供。

本中心特此聲明,我們既非所述產品的測試服務或報告提供者,亦與所述公司概無存在任何持續業務關係。對於所述產品的宣傳資料(「虛假及誤導性信息」)中提及HKMPDC名稱,本中心感到詫異,而此屬於虛假陳述。

為避免令公眾產生任何混淆,本中心已採取行動,要求刪除所有在虛假和誤導性信息中提及HKMPDC名稱的內容,並正尋求對此事進行全面調查。

HKMPDC特此明確保留一切追究權利和補救措施。

The Hong Kong Molecular Pathology Diagnostic Centre
Statement

It has come to the recent attention of The Hong Kong Molecular Pathology Diagnostic Centre (“HKMPDC”) that a company (the “Said Company”) is selling its RT-PCR (reverse transcription polymerase chain reaction) test kits (the “Said Product”) through a number of on-line marketplace and platforms. On some of these platforms, the sales description of the Said Product suggested that the testing service and reports would be provided by, among other parties, HKMPDC.

HKMPDC wishes to put on record that it is neither a testing service or report provider to the Said Product nor is it in any on-going business relations with the Said Company. HKMPDC is astonished to see its name being referred to in the promotional materials of the Said Product (“False and Misleading Information”) which itself is misrepresentation.

To avoid any confusion to the general public, HKMPDC has taken action to demand that all references to its name in the False and Misleading Information be removed. It is also seeking to conduct a full investigation into the matter.

All HKMPDC’s rights and remedies are hereby expressly reserved.
有關預約新型冠狀病毒院舍強制檢測服務請電郵致 covid_onsite@hk-mpdc.com 查詢

請提供以下資料:
院社名稱、地址
聯絡人名稱和電話
預計檢測人數
預定日期和時間

College of American Pathologists, cap.org

EMQN, European Molecular Genetics Quality Network, emqn.org

EMQN, European Molecular Genetics Quality Network, emqn.org

KRAS G12C-AN EMERGING BIOMARKER AND NOVEL INVESTIGATIONAL TARGET IN NON-SMALL CELL LUNG CANCER
 
HKMPDC SARS-CoV-2 RT-PCR is HOKLAS accredited according to ISO15189:2012 Standards.
The ILAC MRA acts as an internationally recognised ‘stamp of approval’ to demonstrate compliance against agreed standards and requirements. The MRA also provides additional confidence to the general public and consumers purchasing our testing services.

HKMPDC SARS-CoV-2 (COVID-19) Real-time RT-PCR Assay received CE-IVD marking
according to the European Standards: Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices

 
HKMPDC is offering COVID-19 (2019-nCoV) real-time RT-PCR test using CE-IVD approved assay.
 
HKMPDC to provide PIK3CA hotspot mutation test for the first FDA approved treatment Piqray (alpelisib) for patient with PIK3CA mutation in HR+/HER2 advanced breast cancer using either tissue or blood sample.
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
 
The First US FDA Approved Non-invasive (BLOOD) EGFR Mutation Test for Lung Cancer Targeted Therapy Using Liquid Biopsy
HKMPDC the first ISO 15189 accredited Molecular Diagnostic Laboratory to provide FDA approved liquid biopsy EGFR test.

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
 
HKMPDC The First HOKLAS ISO 15189:2012 Accredited Laboratory for Molecular Oncology Testing.
ISO 15189 Accredited Hereditary Cancer Genetic Test:
ISO 15189 Accredited Cancer Biomarker Testing for Precision Medicine (Targeted Therapy):
More>>


FoundationOne test, Foundation Medicine

Harmony Prenatal Test in Hong Kong

Counsyl, DNS screening